Commerce Bank Takes $588,000 Position in Supernus Pharmaceuticals, Inc. $SUPN

Commerce Bank purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the second quarter, Holdings Channel reports. The firm purchased 12,639 shares of the specialty pharmaceutical company’s stock, valued at approximately $588,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Rockefeller Capital Management L.P. increased its holdings in Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 660 shares during the period. Torren Management LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth $49,000. EverSource Wealth Advisors LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 2nd quarter worth $51,000. Hantz Financial Services Inc. grew its position in shares of Supernus Pharmaceuticals by 73.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 458 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth $55,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on SUPN. Cantor Fitzgerald raised their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Zacks Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 6th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $62.83.

Supernus Pharmaceuticals Stock Down 1.5%

Shares of NASDAQ:SUPN opened at $44.19 on Friday. The firm has a 50 day moving average of $46.83 and a 200 day moving average of $48.69. The company has a market capitalization of $2.57 billion, a price-to-earnings ratio of -23.02, a price-to-earnings-growth ratio of 0.83 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 52 week low of $42.45 and a 52 week high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The company had revenue of $219.06 million for the quarter, compared to the consensus estimate of $205.31 million. During the same period last year, the business posted $0.40 EPS. The firm’s revenue was up 32.4% compared to the same quarter last year. On average, sell-side analysts expect that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.